UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • May

    17

    Prioritizing Mental Health for our People, Patients, and Purpose

    Mental health is top of mind at UCB as we work to prioritize the well-being of our people and the patients we serve. A core pillar of our sustainable business approach, we understand that delivering innovative solutions for patients begins with supporting the physical, mental, and social well-being of our employees, their families, and communities, now and in the future. This Mental Health Awareness Month, learn how we’re supporting mental wellness for our people, patients, and our purpose. 

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    May

    02

    JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

    Apr

    22

    Contributing to Environmental Sustainability this Earth Day and Every Day

    Apr

    13

    UCB Community Health Fund Supports U.S. Organizations Addressing Mental Health and Young People

    UCB recently announced the funding recipients for the UCB Community Health Fund’s 2021 call for projects, focused on the needs of vulnerable young people in the wake of COVID-19. Three U.S.-based organizations will receive support from the Fund for projects addressing the mental health of vulnerable young people. 

     

    Apr

    02

    Advancing Our Mission to Cure Epilepsy

    With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.

    Apr

    01

    UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

    Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)